Navigation Links
Life Science Labs Reacting to the Economic Crisis
Date:2/11/2009

ARLINGTON, Va., Feb. 11 /PRNewswire/ -- Scientists engaged in biological research and drug discovery are bracing for expected cuts in their 2009 lab budgets. BioInformatics, LLC (www.gene2drug.com), the premier research and advisory firm serving the life science market, has released preliminary data from the company's newest report Prospering in a Down Market: Strategies for Life Science Suppliers.

In this report, we set out to understand current sources of funding for research and drug discovery and what effect the current economic situation will have on each," says Tamara Zemlo, Ph.D., Vice President of Advisory Services. "Our clients need to know scientists' level of concern over the economic crisis and how this may impact anticipated purchases in 14 product categories."

In response to requests from the life science supply industry, BioInformatics, LLC fielded a detailed 45-question survey to more than 500 senior scientists and lab managers working in universities, and pharmaceutical and biotechnology companies. The final results will be published in early March.

Nearly half of respondents surveyed said they are VERY worried that a recession will make it difficult for them to conduct their research and close to two-thirds indicated that their research has already been affected by the current economic recession. According to Zemlo, life sciences will likely fare better than other sectors of the economy but she points out that scientists are employing a variety of ways to stretch their budgets. "Understanding how and where scientists intend to cut back will be essential for suppliers developing effective marketing and sales strategies."

A complimentary pre-publication Executive Summary of the report is available at http://www.gene2drug.com/reports/default.asp?action=details&report_id=200

ABOUT BIOINFORMATICS, LLC

BioInformatics, LLC is the premier research and advisory firm serving the life science industry. By leveraging our professional social network of more than 40,000 biomedical researchers, we have supported more than 300 companies and provided insights that lead to better business decisions. Our assignments include assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.

    For more information contact:
    Mary Follin
    Manager, Marketing/Sales
    BioInformatics, LLC
    2111 Wilson Blvd., Suite 250
    Arlington, VA  22201
    703.778.3080 x13(phone)
    m.follin@gene2drug.com
   http://www.gene2drug.com/


'/>"/>
SOURCE BioInformatics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
5. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
6. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
7. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
8. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
9. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  Eli Lilly and Company (NYSE: ... galcanezumab for the prevention of migraine at the American ... place April 22-28, 2017, in Boston ... at AAN, including safety and patient outcomes data for ... a reduction in monthly migraine headache days among patients ...
(Date:4/20/2017)... ... 20, 2017 , ... NetDimensions appoints Bill Mastin, a learning technology veteran, as ... experience in the learning technologies industry, Mastin joins NetDimensions from the New York office ... (LTG). At LEO, Mastin served as SVP of the North America offices and prior ...
(Date:4/20/2017)... ... April 20, 2017 , ... Parallel6™ , the leader ... announced today that they were named one of the 2017 Top 10 eClinical ... developments in the pharmaceutical industry. , “We take pride in honoring Parallel6 as one ...
(Date:4/20/2017)... HACKENSACK, N.J. and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell technologies ... Chief Executive Officer, will present at the Alliance for Regenerative ... Investor Day on Thursday, April 27, 2017 at 09:40 EDT ... Dr. Ralph Kern , MD, MHSc, Chief Medical Officer ...
Breaking Biology Technology:
(Date:4/13/2017)... 2017 UBM,s Advanced Design and Manufacturing event ... emerging and evolving technology through its 3D Printing and ... alongside the expo portion of the event and feature ... focused on trending topics within 3D printing and smart ... event will take place June 13-15, 2017 at the Jacob ...
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
Breaking Biology News(10 mins):